Free Trial
→ “The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 years (From Weiss Ratings) (Ad)tc pixel Free DHACW Stock Alerts

Digital Health Acquisition (DHACW) Financials

$0.02 0.00 (0.00%)
As of 10/15/2026
Annual Income Statements for Digital Health Acquisition

Annual Income Statements for Digital Health Acquisition

This table shows Digital Health Acquisition's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -3.24 -3.76 -58 -15
Consolidated Net Income / (Loss)		 -3.24 -3.73 -58 -15
Net Income / (Loss) Continuing Operations		 -3.24 -3.64 -58 -15
Total Pre-Tax Income 		-3.06 -1.89 -59 -15
Total Operating Income		 -3.59 -1.87 -62 -9.58
Total Gross Profit		 0.00 3.83 7.18 7.36
Total Revenue		 0.00 5.77 10 15
Operating Revenue		 - 5.77 10 15
Total Cost of Revenue		 0.00 1.93 3.24 7.26
Operating Cost of Revenue		 - 1.93 3.24 7.26
Total Operating Expenses		 3.59 5.71 69 17
Selling, General & Admin Expense		 3.59 1.20 6.55 10
Other Operating Expenses / (Income)		 - 4.42 5.31 6.90
Impairment Charge		 - 0.00 57 0.00
Restructuring Charge		 - 0.09 0.79 0.00
Total Other Income / (Expense), net		 0.54 0.08 2.81 -5.06
Interest Expense		 0.13 0.19 0.86 3.03
Other Income / (Expense), net		 -0.26 0.27 3.66 -2.03
Income Tax Expense		 0.19 1.84 -1.64 0.07
Basic Earnings per Share		 ($0.25) ($0.38) ($5.65) ($0.73)
Weighted Average Basic Shares Outstanding		 12.74M 10.00M 10.21M 20.14M
Diluted Earnings per Share		 ($0.25) ($0.38) ($5.65) ($0.73)
Weighted Average Diluted Shares Outstanding		 12.74M 10.00M 10.21M 20.14M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 47.30M

Quarterly Income Statements for Digital Health Acquisition

This table shows Digital Health Acquisition's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.33 0.06 -0.63 -54 -3.21 -3.96 -2.61 -0.29 -7.85 -2.60 0.85
Consolidated Net Income / (Loss)		 -1.30 0.09 -0.67 -54 -3.21 -3.96 -2.61 -0.29 -7.85 -2.60 0.85
Net Income / (Loss) Continuing Operations		 -1.21 0.09 -0.67 -54 -3.21 -3.96 -1.90 -0.29 -7.85 -2.60 -3.08
Total Pre-Tax Income 		0.94 0.09 -2.34 -54 -3.18 -3.95 -1.90 -0.29 -7.80 -2.58 -3.10
Total Operating Income		 -0.28 0.10 -0.93 -58 -3.03 -1.83 -1.56 -2.06 -3.44 -2.97 -2.70
Total Gross Profit		 2.04 1.23 0.78 2.78 2.38 1.86 0.62 2.07 1.83 1.20 0.21
Total Revenue		 3.02 1.62 1.71 3.35 3.73 3.32 1.06 3.98 3.93 3.16 1.56
Operating Revenue		 - 1.62 1.71 3.35 3.73 3.32 1.06 3.98 3.93 3.16 1.56
Total Cost of Revenue		 0.98 0.39 0.93 0.57 1.35 1.46 0.44 1.91 2.09 1.96 1.36
Operating Cost of Revenue		 - 0.39 0.93 0.57 1.35 1.46 0.44 1.91 2.09 1.96 1.36
Total Operating Expenses		 2.32 1.13 1.71 61 5.41 3.69 2.17 4.13 5.27 4.17 2.90
Selling, General & Admin Expense		 -0.06 0.21 0.57 2.22 3.56 2.03 1.73 2.92 2.92 2.44 2.25
Other Operating Expenses / (Income)		 - 0.89 0.91 1.73 1.77 1.66 0.45 1.21 2.36 1.73 0.65
Total Other Income / (Expense), net		 1.31 -0.01 -1.41 4.38 -0.15 -2.11 -0.35 1.77 -4.36 0.40 -0.40
Interest Expense		 -0.06 0.01 0.34 0.76 -0.26 0.73 0.22 0.76 1.18 0.11 0.08
Other Income / (Expense), net		 1.33 0.00 -1.07 5.14 -0.41 -1.38 -0.12 2.52 -3.18 0.51 -0.32
Income Tax Expense		 - 0.00 -1.68 0.01 0.03 0.01 0.00 0.00 0.05 0.02 -0.02
Net Income / (Loss) Discontinued Operations		 - - - - - - -0.71 - - - 3.93
Weighted Average Basic Shares Outstanding		 10.00M 4.64M 5.30M 15.08M 10.21M 16.31M 16.42M 16.55M 20.14M 47.90M 53.66M
Weighted Average Diluted Shares Outstanding		 10.00M 4.64M 5.30M 15.08M 10.21M 16.31M 16.42M 16.55M 20.14M 47.90M 53.66M
Weighted Average Basic & Diluted Shares Outstanding		 0.00 3.60M 15.27M 15.67M 0.00 - 32.85M 31.35M 47.30M 48.60M 109.44M

Annual Cash Flow Statements for Digital Health Acquisition

This table details how cash moves in and out of Digital Health Acquisition's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.65 -0.11 0.21 4.94
Net Cash From Operating Activities		 -1.39 -0.63 -5.79 -3.45
Net Cash From Continuing Operating Activities		 -1.39 -0.63 -5.79 -3.45
Net Income / (Loss) Continuing Operations		 -3.24 -3.73 -58 -15
Consolidated Net Income / (Loss)		 -3.24 -3.73 -58 -15
Depreciation Expense		 - 0.00 1.32 2.59
Amortization Expense		 - 0.09 0.06 0.07
Non-Cash Adjustments To Reconcile Net Income		 -0.67 0.03 55 4.59
Changes in Operating Assets and Liabilities, net		 2.52 2.97 -4.68 4.02
Net Cash From Investing Activities		 110 -0.00 -0.03 -0.03
Net Cash From Continuing Investing Activities		 110 -0.00 -0.03 -0.03
Purchase of Property, Plant & Equipment		 - -0.00 -0.06 -0.03
Divestitures		 - 0.00 0.03 0.00
Net Cash From Financing Activities		 -109 0.53 6.02 8.42
Net Cash From Continuing Financing Activities		 -109 0.53 6.02 8.42
Repayment of Debt		 -0.06 0.00 -0.52 1.61
Repurchase of Common Equity		 -110 - -0.01 -0.00
Payment of Dividends		 - 0.00 0.00 -0.01
Issuance of Debt		 1.15 0.39 5.46 0.00
Issuance of Common Equity		 - - 0.00 7.02
Other Financing Activities, net		 0.00 0.00 1.09 -0.20
Cash Interest Paid		 - 0.00 0.11 0.21

Quarterly Cash Flow Statements for Digital Health Acquisition

This table details how cash moves in and out of Digital Health Acquisition's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -0.04 0.57 0.42 1.22 -2.00 0.10 -0.14 0.18 4.79 -3.92 -0.68
Net Cash From Operating Activities		 -0.11 0.58 -3.17 -0.22 -2.97 -0.44 -0.32 -0.75 -1.93 -2.45 -1.17
Net Cash From Continuing Operating Activities		 -0.11 0.58 -3.17 -0.22 -2.97 -0.42 -0.34 -0.75 -1.93 -2.45 -0.05
Net Income / (Loss) Continuing Operations		 -2.74 0.09 -0.67 -54 -3.21 -3.96 -2.61 -0.29 -7.85 -2.60 0.85
Consolidated Net Income / (Loss)		 -2.74 0.09 -0.67 -54 -3.21 -3.96 -2.61 -0.29 -7.85 -2.60 -1.74
Depreciation Expense		 0.00 0.00 0.00 0.65 0.67 0.65 0.65 0.65 0.65 0.65 0.64
Amortization Expense		 0.00 0.01 0.00 0.01 0.04 0.02 0.02 0.02 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 -0.16 0.01 1.65 53 0.82 1.91 0.74 -2.30 4.20 0.29 1.26
Changes in Operating Assets and Liabilities, net		 2.79 0.47 -4.16 0.32 -1.30 0.96 0.86 1.17 1.07 -0.78 0.01
Net Cash From Investing Activities		 -0.00 -0.01 -0.01 -0.00 -0.00 -0.01 -0.00 -0.01 -0.01 -0.13 -0.00
Net Cash From Continuing Investing Activities		 -0.00 -0.01 -0.01 -0.00 -0.00 -0.01 -0.00 -0.01 -0.01 -0.13 -0.07
Purchase of Property, Plant & Equipment		 -0.00 -0.01 -0.04 -0.00 -0.00 -0.01 -0.00 -0.01 -0.01 -0.03 -0.07
Net Cash From Financing Activities		 0.07 0.00 3.60 1.45 0.98 0.54 0.21 0.94 6.73 -1.34 0.50
Net Cash From Continuing Financing Activities		 0.07 0.00 3.60 1.45 0.98 0.54 0.21 0.94 6.73 -1.34 0.50
Repayment of Debt		 - 0.00 -0.41 -0.04 -0.07 0.00 -0.00 -0.64 2.28 -0.88 -0.25
Issuance of Debt		 0.07 0.00 2.70 2.00 0.76 0.51 0.22 1.18 -1.91 0.18 -0.00
Issuance of Common Equity		 - 0.00 - - - 0.09 - 0.45 6.48 0.00 0.00
Other Financing Activities, net		 - 0.00 1.31 -0.52 0.30 -0.05 -0.01 -0.05 -0.12 -0.59 0.59
Cash Interest Paid		 - 0.00 - 0.01 0.10 0.11 0.03 0.15 -0.07 0.21 0.21

Annual Balance Sheets for Digital Health Acquisition

This table presents Digital Health Acquisition's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 118 7.63 0.81 20 22
Total Current Assets		 1.22 0.11 0.80 3.02 8.37
Cash & Equivalents		 0.76 0.11 0.12 0.33 5.05
Accounts Receivable		 - - 0.60 2.25 2.55
Prepaid Expenses		 0.46 - 0.08 0.45 0.14
Other Current Nonoperating Assets		 - - - - 0.63
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.68 0.29
Total Noncurrent Assets		 117 7.53 0.00 16 14
Long-Term Investments		 - - - - 0.00
Goodwill		 - - 0.00 4.92 4.92
Intangible Assets		 - - 0.00 11 8.79
Other Noncurrent Operating Assets		 117 7.53 0.00 0.38 0.01
Other Noncurrent Nonoperating Assets		 - - - - 0.04
Total Liabilities & Shareholders' Equity		 118 7.63 0.81 20 22
Total Liabilities		 4.55 7.67 5.11 20 17
Total Current Liabilities		 0.18 3.30 5.11 19 16
Short-Term Debt		 0.00 0.00 0.92 7.85 1.31
Accounts Payable		 0.14 1.89 2.59 9.34 9.33
Other Current Liabilities		 0.04 1.22 0.69 1.33 1.74
Other Current Nonoperating Liabilities		 - 0.00 - - 3.86
Total Noncurrent Liabilities		 4.37 4.37 0.00 1.07 0.72
Long-Term Debt		 - - 0.00 0.59 0.59
Capital Lease Obligations		 - - - - 0.00
Noncurrent Deferred & Payable Income Tax Liabilities		 - - 0.00 0.07 0.12
Other Noncurrent Operating Liabilities		 4.37 4.37 0.00 0.34 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -3.33 -7.43 -4.30 -0.02 5.45
Total Preferred & Common Equity		 -3.33 -7.43 -3.97 -0.02 5.45
Preferred Stock		 - - 0.00 0.00 0.00
Total Common Equity		 -3.33 -7.43 -3.97 -0.02 5.45
Common Stock		 0.00 0.29 6.03 68 88
Retained Earnings		 -3.33 -7.72 -10 -68 -82

Quarterly Balance Sheets for Digital Health Acquisition

This table presents Digital Health Acquisition's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 8.14 1.39 79 25 19 18 19 19 17
Total Current Assets		 0.02 0.00 5.17 7.11 3.08 2.56 3.72 4.84 3.27
Cash & Equivalents		 0.00 - 1.11 2.33 0.41 0.29 0.47 1.35 0.45
Accounts Receivable		 - - 3.30 3.17 2.14 1.86 2.86 2.98 2.55
Prepaid Expenses		 0.02 - 0.76 1.61 0.53 0.41 0.38 0.51 0.27
Other Current Nonoperating Assets		 - - - - - - - - 0.00
Plant, Property, & Equipment, net		 0.00 0.00 0.88 0.79 0.60 0.51 0.42 0.27 0.11
Total Noncurrent Assets		 8.12 1.39 73 17 16 15 15 14 13
Long-Term Investments		 - - - - - - - 0.75 0.75
Goodwill		 - - 60 4.92 4.92 4.92 4.92 4.92 4.92
Intangible Assets		 - - 12 12 10 9.89 9.34 8.23 7.68
Other Noncurrent Operating Assets		 8.12 1.39 0.69 0.42 0.36 0.34 0.32 0.01 0.01
Other Noncurrent Nonoperating Assets		 - - - - - - - - 0.00
Total Liabilities & Shareholders' Equity		 8.14 1.39 79 25 19 18 19 19 17
Total Liabilities		 9.39 13 24 20 23 24 24 13 9.14
Total Current Liabilities		 5.02 8.97 23 19 22 23 23 12 8.10
Short-Term Debt		 0.88 3.45 12 8.56 9.70 9.97 7.87 1.34 1.23
Accounts Payable		 2.77 3.64 6.75 8.27 9.46 9.62 12 8.53 6.40
Other Current Liabilities		 1.19 1.54 2.73 1.63 1.92 2.24 2.65 0.48 0.47
Other Current Nonoperating Liabilities		 - - - - - - - - 0.00
Total Noncurrent Liabilities		 4.37 4.37 1.30 1.06 0.97 0.95 0.89 0.90 1.05
Long-Term Debt		 - - 0.59 0.59 0.59 0.59 0.59 0.78 0.78
Capital Lease Obligations		 - - - 0.18 - - - 0.00 0.00
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - 0.07 0.07 0.07 0.12 0.12
Other Noncurrent Operating Liabilities		 4.37 4.37 0.70 0.29 0.31 0.29 0.23 - 0.15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -9.15 -13 55 4.76 -3.50 -5.74 -5.58 6.32 7.59
Total Preferred & Common Equity		 -9.15 -13 55 4.76 -3.50 -5.74 -5.58 6.32 7.59
Preferred Stock		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -9.15 -13 55 4.76 -3.50 -5.74 -5.58 6.32 7.59
Common Stock		 0.62 0.55 65 66 68 69 69 91 92
Retained Earnings		 -9.77 -14 -9.77 -62 -72 -74 -75 -85 -84

Annual Metrics And Ratios for Digital Health Acquisition

This table displays calculated financial ratios and metrics derived from Digital Health Acquisition's official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 4,126,123.00 3,583,966.00 15,670,936.00 32,845,380.00
DEI Adjusted Shares Outstanding		 4,126,123.00 3,583,966.00 15,670,936.00 32,845,380.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.79 -1.05 -3.68 -0.45
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 80.74% 40.27%
EBITDA Growth		 0.00% 60.77% -3,678.98% 84.31%
EBIT Growth		 0.00% 58.32% -3,543.08% 80.15%
NOPAT Growth		 0.00% 47.88% -3,217.21% 84.58%
Net Income Growth		 0.00% -14.89% -1,448.86% 74.50%
EPS Growth		 0.00% -52.00% -1,386.84% 87.08%
Operating Cash Flow Growth		 0.00% 54.53% -815.21% 40.48%
Free Cash Flow Firm Growth		 0.00% 0.00% -2,793.67% 98.13%
Invested Capital Growth		 0.00% -2,428.30% 331.69% -70.11%
Revenue Q/Q Growth		 0.00% 110.30% 7.31% 1.33%
EBITDA Q/Q Growth		 0.00% 63.26% -7.09% -56.81%
EBIT Q/Q Growth		 0.00% 60.97% -8.31% -37.78%
NOPAT Q/Q Growth		 0.00% 32.93% -4.62% -4.49%
Net Income Q/Q Growth		 0.00% -1.88% -3.41% -46.10%
EPS Q/Q Growth		 0.00% 43.28% -60.51% 69.33%
Operating Cash Flow Q/Q Growth		 0.00% 47.27% -97.97% 23.32%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -2.55% -135.14%
Invested Capital Q/Q Growth		 0.00% -820.11% -31.17% 0.40%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 66.47% 68.87% 50.32%
EBITDA Margin		 0.00% -26.21% -547.93% -61.28%
Operating Margin		 0.00% -32.49% -596.38% -65.55%
EBIT Margin		 0.00% -27.84% -561.23% -79.43%
Profit (Net Income) Margin		 0.00% -64.61% -553.69% -100.65%
Tax Burden Percent		 106.13% 197.43% 97.23% 100.47%
Interest Burden Percent		 79.32% 117.54% 101.47% 126.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -1,890.38% -127.54%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -2,208.66% -442.38%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 4,563.01% -413.98%
Return on Equity (ROE)		 -5.72% 172.05% 2,672.62% -541.52%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -680.39% -19.60%
Operating Return on Assets (OROA)		 0.00% -38.04% -562.43% -54.76%
Return on Assets (ROA)		 0.00% -88.28% -554.87% -69.39%
Return on Common Equity (ROCE)		 0.54% 452.91% 2,471.29% -541.52%
Return on Equity Simple (ROE_SIMPLE)		 43.66% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.52 -1.31 -44 -6.71
NOPAT Margin		 0.00% -22.75% -417.47% -45.89%
Net Nonoperating Expense Percent (NNEP)		 -678.54% 692.40% 318.28% 314.83%
Return On Investment Capital (ROIC_SIMPLE)		 - 38.84% -516.44% -87.26%
Cost of Revenue to Revenue		 0.00% 33.53% 31.13% 49.68%
SG&A Expenses to Revenue		 0.00% 20.85% 62.89% 68.66%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 98.97% 665.25% 115.88%
Earnings before Interest and Taxes (EBIT)		 -3.85 -1.61 -58 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.85 -1.51 -57 -8.96
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 7.58 2.05 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 3.63 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 7.67 2.82 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 21.61 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 -0.21 -456.66 0.41
Long-Term Debt to Equity		 0.00 0.00 -32.13 0.11
Financial Leverage		 3.42 -0.16 -2.07 0.94
Leverage Ratio		 1.11 -1.95 -4.82 7.80
Compound Leverage Factor		 0.88 -2.29 -4.89 9.84
Debt to Total Capital		 0.00% -27.34% 100.22% 29.07%
Short-Term Debt to Total Capital		 0.00% -27.34% 93.17% 21.35%
Long-Term Debt to Total Capital		 0.00% 0.00% 7.05% 7.73%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -23,667.39% 9.63% 0.00% 0.00%
Common Equity to Total Capital		 23,767.39% 117.70% -0.22% 70.93%
Debt to EBITDA		 0.00 -0.61 -0.15 -0.25
Net Debt to EBITDA		 0.00 -0.53 -0.14 0.34
Long-Term Debt to EBITDA		 0.00 0.00 -0.01 -0.07
Debt to NOPAT		 0.00 -0.70 -0.19 -0.33
Net Debt to NOPAT		 0.00 -0.61 -0.19 0.45
Long-Term Debt to NOPAT		 0.00 0.00 -0.01 -0.09
Altman Z-Score		 -0.06 -18.07 -14.19 0.00
Noncontrolling Interest Sharing Ratio		 109.49% -163.25% 7.53% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.03 0.16 0.16 0.52
Quick Ratio		 0.03 0.14 0.14 0.50
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 2.05 -55 -1.03
Operating Cash Flow to CapEx		 0.00% -14,592.73% -10,475.59% -11,513.41%
Free Cash Flow to Firm to Interest Expense		 0.00 10.69 -64.26 -0.34
Operating Cash Flow to Interest Expense		 -11.04 -3.31 -6.75 -1.14
Operating Cash Flow Less CapEx to Interest Expense		 -11.04 -3.33 -6.82 -1.15
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 1.37 1.00 0.69
Accounts Receivable Turnover		 0.00 0.00 7.31 5.76
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 30.48 28.87
Accounts Payable Turnover		 0.00 0.86 0.54 0.70
Days Sales Outstanding (DSO)		 0.00 0.00 49.94 63.34
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 422.23 671.20 524.73
Cash Conversion Cycle (CCC)		 0.00 -422.23 -621.26 -461.39
Capital & Investment Metrics		 - - - -
Invested Capital		 -0.14 -3.50 8.10 2.42
Invested Capital Turnover		 0.00 -3.17 4.53 2.78
Increase / (Decrease) in Invested Capital		 0.00 -3.36 12 -5.68
Enterprise Value (EV)		 52 44 29 0.00
Market Capitalization		 45 44 21 0.00
Book Value per Share		 ($1.80) ($1.11) $0.00 $0.27
Tangible Book Value per Share		 ($1.80) ($1.11) ($1.02) ($0.41)
Total Capital		 -0.03 -3.38 8.42 7.69
Total Debt		 0.00 0.92 8.44 2.23
Total Long-Term Debt		 0.00 0.00 0.59 0.59
Net Debt		 -0.11 0.80 8.12 -3.03
Capital Expenditures (CapEx)		 0.00 0.00 0.06 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.30 -3.50 -8.47 -12
Debt-free Net Working Capital (DFNWC)		 -3.19 -3.38 -8.14 -6.24
Net Working Capital (NWC)		 -3.19 -4.30 -16 -7.88
Net Nonoperating Expense (NNE)		 0.73 2.41 14 8.00
Net Nonoperating Obligations (NNO)		 -0.11 0.80 8.12 -3.03
Total Depreciation and Amortization (D&A)		 0.00 0.09 1.39 2.65
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -60.68% -81.24% -78.70%
Debt-free Net Working Capital to Revenue		 0.00% -58.62% -78.11% -42.68%
Net Working Capital to Revenue		 0.00% -74.63% -153.43% -53.90%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 ($0.25) ($1.08) $0.00 ($0.73)
Adjusted Weighted Average Basic Shares Outstanding		 12.74M 4.10M 0.00 20.14M
Adjusted Diluted Earnings per Share		 ($0.25) ($1.08) $0.00 ($0.73)
Adjusted Weighted Average Diluted Shares Outstanding		 12.74M 4.10M 0.00 20.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 47.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.52 -1.25 -3.28 -6.71
Normalized NOPAT Margin		 0.00% -21.69% -31.45% -45.89%
Pre Tax Income Margin		 0.00% -32.73% -569.46% -100.18%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -30.58 -8.39 -68.21 -3.83
NOPAT to Interest Expense		 -19.98 -6.86 -50.74 -2.21
EBIT Less CapEx to Interest Expense		 -30.58 -8.41 -68.28 -3.84
NOPAT Less CapEx to Interest Expense		 -19.98 -6.88 -50.80 -2.22
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% -0.07%
Augmented Payout Ratio		 -3,407.01% 0.00% -0.01% -0.07%

Quarterly Metrics And Ratios for Digital Health Acquisition

This table displays calculated financial ratios and metrics derived from Digital Health Acquisition's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 3,583,966.00 3,583,966.00 3,603,966.00 15,268,436.00 15,670,936.00 15,670,936.00 15,670,936.00 32,845,380.00 32,845,380.00 32,845,380.00 48,599,421.00
DEI Adjusted Shares Outstanding		 3,583,966.00 3,583,966.00 3,603,966.00 15,268,436.00 15,670,936.00 15,670,936.00 15,670,936.00 32,845,380.00 32,845,380.00 32,845,380.00 48,599,421.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.37 0.02 -0.18 -3.53 -0.20 -0.25 -0.17 -0.01 -0.24 -0.08 0.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 32.66% 131.11% 23.48% 104.90% 98.07% 18.67% 5.13% -4.86% 48.02%
EBITDA Growth		 172.15% 106.08% -281.87% -18,824.39% -359.31% -2,381.30% 21.25% 102.16% -119.03% 28.78% -133.79%
EBIT Growth		 172.08% 105.67% -282.83% -17,857.80% -427.15% -3,189.82% -11.96% 100.88% -92.64% 23.38% -79.64%
NOPAT Growth		 66.61% 121.01% -52.59% -21,147.94% -655.46% -1,331.91% -141.79% 96.47% -13.61% -62.41% -73.34%
Net Income Growth		 -5.57% 105.00% -55.42% -54,598.74% -146.09% -4,278.83% -292.32% 99.46% -144.70% 34.33% 132.42%
EPS Growth		 241.67% 102.22% -33.33% -35,700.00% -1,252.94% -2,500.00% -33.33% 99.44% 84.18% 79.17% 0.00%
Operating Cash Flow Growth		 83.86% 270.04% -2,268.71% -353.00% -2,624.74% -176.04% 89.77% -241.37% 35.24% -456.69% -261.59%
Free Cash Flow Firm Growth		 0.00% -93.61% -160.57% -147.48% -545.72% -322.64% 189.05% 114.94% 123.84% 87.30% -109.43%
Invested Capital Growth		 -2,428.30% -547.28% 10,006.07% 3,197.01% 331.69% 175.78% -93.19% -79.50% -70.11% -0.59% 85.16%
Revenue Q/Q Growth		 108.35% -46.40% 5.59% 95.99% 11.33% -11.06% 2.07% 17.42% -1.37% -19.50% -50.58%
EBITDA Q/Q Growth		 479.09% -89.38% -1,888.75% -2,527.55% 94.81% 6.56% 38.25% 172.16% -626.05% 69.62% -30.89%
EBIT Q/Q Growth		 454.90% -90.09% -2,024.52% -2,554.10% 93.53% 6.44% 30.27% 120.79% -1,520.26% 62.79% -22.50%
NOPAT Q/Q Growth		 -46.06% 137.10% -727.30% -6,151.32% 94.81% 39.51% -23.12% 8.75% -67.16% 13.52% 9.31%
Net Income Q/Q Growth		 -1,222.42% 107.27% -803.01% -7,995.24% 94.05% -23.42% 34.00% 88.91% -2,609.41% 66.88% 132.58%
EPS Q/Q Growth		 1,800.00% -94.12% -1,300.00% -2,883.33% 45.25% 87.76% 33.33% 87.50% -1,450.00% 83.87% 0.00%
Operating Cash Flow Q/Q Growth		 -123.72% 630.68% -647.83% 93.04% -1,245.63% 85.19% 26.31% -132.45% -155.27% -27.31% 52.14%
Free Cash Flow Firm Q/Q Growth		 -97.24% 135.01% -1,040.46% 22.13% 74.10% -17.39% 476.18% -86.93% -58.68% -162.53% -181.41%
Invested Capital Q/Q Growth		 -820.11% -141.13% 891.04% -82.35% -31.17% -21.13% -28.94% -46.87% 0.40% 162.27% 32.36%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 67.58% 76.17% 45.40% 83.02% 63.76% 56.00% 46.86% 52.08% 46.72% 37.91% 13.20%
EBITDA Margin		 34.77% 6.89% -116.71% -1,564.77% -73.01% -76.70% -46.41% 28.52% -152.11% -57.41% -152.05%
Operating Margin		 -9.28% 6.42% -54.48% -1,737.85% -81.07% -55.14% -66.51% -51.69% -87.61% -94.12% -172.70%
EBIT Margin		 34.73% 6.42% -117.01% -1,584.54% -92.02% -96.80% -66.14% 11.71% -168.63% -77.95% -193.21%
Profit (Net Income) Margin		 -43.11% 5.85% -38.92% -1,607.50% -85.91% -119.21% -77.09% -7.28% -199.96% -82.28% 54.25%
Tax Burden Percent		 -138.25% 100.00% 28.41% 100.02% 100.84% 100.34% 100.17% 100.00% 100.65% 100.92% -27.35%
Interest Burden Percent		 89.77% 91.05% 117.07% 101.43% 92.58% 122.72% 116.36% -62.16% 117.82% 104.59% 102.67%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -9.02% -2,075.33% -256.97% 0.00% -18.05% -73.64% -170.44% -149.56% -279.53%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -9.24% -2,408.22% -281.38% 0.00% -27.40% -58.29% -384.51% -160.02% -230.18%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% -2.16% -5,414.88% 581.32% 0.00% -12.36% 1,070.42% -359.83% -561.66% -1,374.55%
Return on Equity (ROE)		 172.05% 25.41% -11.19% -7,490.21% 324.35% 799.50% -30.40% 996.77% -530.28% -711.22% -1,654.08%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -102.46% -456.68% -680.39% -934.33% 45.91% 41.39% -19.60% -117.31% -188.09%
Operating Return on Assets (OROA)		 47.46% 10.47% -20.99% -927.89% -92.22% -112.92% -18.78% 7.72% -116.26% -58.68% -165.47%
Return on Assets (ROA)		 -58.90% 9.53% -6.98% -941.33% -86.09% -139.06% -21.89% -4.80% -137.86% -61.94% 46.46%
Return on Common Equity (ROCE)		 452.91% 41.55% -9.56% 9,381.55% 299.92% 865.84% -30.40% 996.78% -530.28% -711.22% -1,654.08%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.28 0.10 -0.65 -41 -2.12 -1.28 -1.58 -1.44 -2.41 -2.08 -1.89
NOPAT Margin		 -9.28% 6.42% -38.14% -1,216.49% -56.75% -38.59% -46.56% -36.18% -61.32% -65.88% -120.89%
Net Nonoperating Expense Percent (NNEP)		 293.47% 0.47% 0.21% 332.89% 24.41% 39.94% 9.35% -15.35% 214.07% 10.46% -49.35%
Return On Investment Capital (ROIC_SIMPLE)		 8.31% -1.06% -0.96% -289.57% -25.16% -18.86% -32.68% -49.94% -31.32% -24.65% -19.65%
Cost of Revenue to Revenue		 32.42% 23.83% 54.60% 16.98% 36.24% 44.00% 53.14% 47.92% 53.28% 62.09% 86.80%
SG&A Expenses to Revenue		 -1.86% 13.00% 33.21% 66.13% 95.24% 61.19% 64.09% 73.28% 74.25% 77.22% 144.31%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 76.85% 69.75% 99.88% 1,820.86% 144.83% 111.13% 113.37% 103.77% 134.33% 132.03% 185.90%
Earnings before Interest and Taxes (EBIT)		 1.05 0.10 -2.00 -53 -3.44 -3.22 -2.24 0.47 -6.62 -2.46 -3.02
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.05 0.11 -2.00 -52 -2.73 -2.55 -1.57 1.14 -5.97 -1.81 -2.37
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.58 4.78 0.00 0.00 0.00 0.00 0.00 0.00 0.74
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 7.58 5.72 4.04 2.34 2.05 1.55 1.32 0.69 0.00 0.00 0.38
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.65 2.53 3.63 4.49 6.27 7.47 0.00 0.00 0.77
Enterprise Value to Revenue (EV/Rev)		 7.67 6.36 5.56 3.06 2.82 2.37 2.06 1.25 0.00 0.00 0.43
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 140.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 140.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 163.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 21.61 7.75 0.00 0.00 0.00 0.00 1.74 6.14 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.21 -0.29 0.24 1.96 -456.66 -2.94 -1.84 -1.52 0.41 0.34 0.27
Long-Term Debt to Equity		 0.00 0.00 0.01 0.16 -32.13 -0.17 -0.10 -0.11 0.11 0.12 0.10
Financial Leverage		 -0.16 -0.29 0.23 2.25 -2.07 -0.87 0.45 -18.36 0.94 3.51 5.97
Leverage Ratio		 -1.95 -0.66 1.63 9.46 -4.82 -1.35 1.98 -53.57 7.80 13.60 18.82
Compound Leverage Factor		 -1.75 -0.60 1.91 9.60 -4.46 -1.65 2.30 33.30 9.19 14.23 19.33
Debt to Total Capital		 -27.34% -40.52% 19.13% 66.23% 100.22% 151.45% 218.76% 293.32% 29.07% 25.15% 20.97%
Short-Term Debt to Total Capital		 -27.34% -40.52% 18.25% 60.73% 93.17% 142.71% 206.46% 272.89% 21.35% 15.90% 12.84%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.88% 5.50% 7.05% 8.74% 12.30% 20.44% 7.73% 9.25% 8.13%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 9.63% -15.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 117.70% 155.59% 80.87% 33.77% -0.22% -51.45% -118.76% -193.32% 70.93% 74.85% 79.03%
Debt to EBITDA		 -0.61 10.28 -11.66 -0.18 -0.15 -0.17 -0.18 -1.48 -0.25 -0.26 -0.21
Net Debt to EBITDA		 -0.53 10.28 -10.67 -0.13 -0.14 -0.17 -0.17 -1.40 0.34 0.00 -0.08
Long-Term Debt to EBITDA		 0.00 0.00 -0.53 -0.01 -0.01 -0.01 -0.01 -0.10 -0.07 -0.10 -0.08
Debt to NOPAT		 -0.70 -3.25 -13.39 -0.22 -0.19 -0.23 -0.23 -1.32 -0.33 -0.28 -0.24
Net Debt to NOPAT		 -0.61 -3.25 -12.25 -0.17 -0.19 -0.22 -0.22 -1.24 0.45 0.00 -0.10
Long-Term Debt to NOPAT		 0.00 0.00 -0.61 -0.02 -0.01 -0.01 -0.01 -0.09 -0.09 -0.10 -0.09
Altman Z-Score		 -7.19 -14.20 0.36 -9.97 -5.11 -5.77 -6.25 -5.74 0.00 0.00 -6.72
Noncontrolling Interest Sharing Ratio		 -163.25% -63.51% 14.58% 225.25% 7.53% -8.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.16 0.00 0.23 0.37 0.16 0.14 0.11 0.16 0.52 0.41 0.40
Quick Ratio		 0.14 0.00 0.19 0.29 0.14 0.12 0.09 0.14 0.50 0.37 0.37
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 3.08 7.23 -68 -53 -14 -16 61 7.91 3.27 -2.04 -5.75
Operating Cash Flow to CapEx		 -6,635.81% 6,627.99% -8,629.97% -4,425.99% -62,485.17% -3,710.04% -9,034.26% -10,322.00% -26,930.94% -9,166.38% -1,602.40%
Free Cash Flow to Firm to Interest Expense		 0.00 776.59 -198.91 -69.55 0.00 -22.03 165.13 10.47 2.77 -18.08 -71.29
Operating Cash Flow to Interest Expense		 0.00 62.22 -9.28 -0.29 0.00 -0.60 -0.89 -1.00 -1.63 -21.68 -14.54
Operating Cash Flow Less CapEx to Interest Expense		 0.00 61.28 -9.39 -0.30 0.00 -0.62 -0.90 -1.01 -1.64 -21.92 -15.45
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.37 1.63 0.18 0.59 1.00 1.17 0.28 0.66 0.69 0.75 0.86
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 7.31 0.00 5.35 4.78 5.76 5.64 6.79
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 30.48 0.00 19.87 23.78 28.87 33.51 48.33
Accounts Payable Turnover		 0.86 0.80 0.61 0.52 0.54 0.66 0.63 0.65 0.70 0.86 1.08
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 49.94 0.00 68.21 76.37 63.34 64.68 53.72
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 422.23 454.64 595.04 701.72 671.20 553.57 576.20 559.13 524.73 422.89 336.83
Cash Conversion Cycle (CCC)		 -422.23 -454.64 -595.04 -701.72 -621.26 -553.57 -508.00 -482.77 -461.39 -358.20 -283.11
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.50 -8.43 67 12 8.10 6.39 4.54 2.41 2.42 6.35 8.40
Invested Capital Turnover		 -3.17 -1.52 0.24 1.71 4.53 -11.88 0.39 2.04 2.78 2.27 2.31
Increase / (Decrease) in Invested Capital		 -3.36 -7.13 67 12 12 15 -62 -9.35 -5.68 -0.04 3.87
Enterprise Value (EV)		 44 47 43 30 29 29 28 18 0.00 0.00 6.43
Market Capitalization		 44 42 32 23 21 19 18 10 0.00 0.00 5.62
Book Value per Share		 ($1.11) ($3.69) $15.21 $0.31 $0.00 ($0.22) ($0.37) ($0.34) $0.27 $0.13 $0.16
Tangible Book Value per Share		 ($1.11) ($3.69) ($4.77) ($0.77) ($1.02) ($1.20) ($1.31) ($1.21) ($0.41) ($0.14) ($0.10)
Total Capital		 -3.38 -8.51 68 14 8.42 6.80 4.83 2.88 7.69 8.45 9.61
Total Debt		 0.92 3.45 13 9.33 8.44 10 11 8.46 2.23 2.12 2.02
Total Long-Term Debt		 0.00 0.00 0.59 0.78 0.59 0.59 0.59 0.59 0.59 0.78 0.78
Net Debt		 0.80 3.45 12 7.01 8.12 9.88 10 7.99 -3.03 0.03 0.81
Capital Expenditures (CapEx)		 0.00 0.01 0.04 0.00 0.00 0.01 0.00 0.01 0.01 0.03 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.50 -5.52 -6.45 -5.87 -8.47 -9.61 -11 -12 -12 -6.96 -4.05
Debt-free Net Working Capital (DFNWC)		 -3.38 -5.52 -5.34 -3.54 -8.14 -9.20 -11 -12 -6.24 -5.61 -3.60
Net Working Capital (NWC)		 -4.30 -8.97 -18 -12 -16 -19 -20 -20 -7.88 -6.95 -4.83
Net Nonoperating Expense (NNE)		 1.02 0.01 0.01 13 1.09 2.68 1.03 -1.15 5.44 0.52 -2.74
Net Nonoperating Obligations (NNO)		 0.80 3.52 12 7.01 8.12 9.88 10 7.99 -3.03 0.03 0.81
Total Depreciation and Amortization (D&A)		 0.00 0.01 0.01 0.66 0.71 0.67 0.67 0.67 0.65 0.65 0.64
Debt-free, Cash-free Net Working Capital to Revenue		 -60.68% -74.75% -82.58% -60.43% -81.24% -79.30% -78.39% -85.30% -78.70% -48.12% -27.07%
Debt-free Net Working Capital to Revenue		 -58.62% -74.75% -68.42% -36.46% -78.11% -75.92% -76.27% -82.03% -42.68% -38.81% -24.03%
Net Working Capital to Revenue		 -74.63% -121.41% -226.85% -124.59% -153.43% -155.94% -148.54% -136.58% -53.90% -48.10% -32.27%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.17 ($0.27) ($0.06) ($3.43) ($1.96) ($0.24) ($0.16) ($0.02) ($0.31) ($0.05) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 10.00M 3.60M 5.30M 15.08M 10.21M 16.31M 16.42M 16.55M 20.14M 47.90M 53.66M
Adjusted Diluted Earnings per Share		 $0.17 ($0.27) ($0.06) ($3.43) ($1.96) ($0.24) ($0.16) ($0.02) ($0.31) ($0.05) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 10.00M 3.60M 5.30M 15.08M 10.21M 16.31M 16.42M 16.55M 20.14M 47.90M 53.66M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 3.60M 15.27M 15.67M 0.00 0.00 0.00 31.35M 47.30M 48.60M 109.44M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.20 0.09 -0.49 -0.81 -2.06 -1.28 -1.58 -1.44 -2.41 -2.08 -1.89
Normalized NOPAT Margin		 -6.49% 5.63% -28.80% -24.29% -55.20% -38.59% -46.56% -36.18% -61.32% -65.88% -120.89%
Pre Tax Income Margin		 31.18% 5.85% -136.98% -1,607.24% -85.19% -118.80% -76.95% -7.28% -198.68% -81.53% -198.37%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 11.18 -5.86 -69.81 0.00 -4.40 -6.11 0.62 -5.61 -21.78 -37.39
NOPAT to Interest Expense		 0.00 11.18 -1.91 -53.60 0.00 -1.75 -4.30 -1.91 -2.04 -18.41 -23.40
EBIT Less CapEx to Interest Expense		 0.00 10.24 -5.97 -69.82 0.00 -4.42 -6.12 0.61 -5.62 -22.02 -38.30
NOPAT Less CapEx to Interest Expense		 0.00 10.24 -2.02 -53.60 0.00 -1.77 -4.31 -1.92 -2.05 -18.65 -24.30
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.02% -0.02% -0.15% -0.07% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -0.01% -0.02% -0.02% -0.15% -0.07% -0.37% -0.51%

Financials Breakdown Chart

Key Financial Trends

VSee Health’s latest statements show improved liquidity compared with 2025, but the company remains structurally unprofitable and dependent on outside financing. Revenue reached $1.56 million in Q2 2026, up from $1.06 million in Q2 2025 but down sharply from $3.16 million in Q1 2026. The quarter’s reported consolidated net income of $847,000 was largely driven by a $3.93 million gain from discontinued operations; continuing operations still produced a $3.08 million net loss.

Profitability has deteriorated from early 2024 levels. VSee reported modest net income in Q1 2024, but recorded continuing-operation losses in every reported quarter afterward. Operating losses were $1.83 million in Q1 2025, $2.06 million in Q3 2025, $3.44 million in Q4 2025, $2.97 million in Q1 2026 and $2.70 million in Q2 2026. Although the operating loss improved slightly sequentially, gross margin fell to approximately 13% in Q2 2026 from 38% in Q1 and 58% in Q2 2025.

The balance sheet has improved from the severe negative-equity position reported during 2025. Total equity was negative $5.6 million in Q3 2025 and negative $5.7 million in Q2 2025, but increased to positive $7.6 million by Q2 2026. However, this improvement primarily reflects substantial equity issuance and remains offset by accumulated retained losses of $84.2 million.

Cash generation remains a major concern. Operating cash flow was negative $1.17 million in Q2 2026, following a negative $2.45 million in Q1. Cash and equivalents fell from $1.35 million at the end of Q1 2026 to only $454,000 at June 30, 2026. With $8.10 million of current liabilities and $3.27 million of current assets, the company’s current ratio was approximately 0.40.

  • Revenue is higher year over year: Q2 2026 revenue of $1.56 million was approximately 48% above the restated Q2 2025 level of $1.06 million.
  • Equity returned to a positive balance: Total equity improved from negative $5.6 million in Q3 2025 to positive $7.6 million in Q2 2026, reducing the immediate risk associated with negative book value.
  • Debt balances have declined: Short- and long-term debt totaled approximately $2.02 million in Q2 2026, down from $2.12 million in Q1 2026 and substantially below the $8.46 million reported in Q2 2025.
  • Operating cash burn improved sequentially: Cash used in operating activities declined from $2.45 million in Q1 2026 to $1.17 million in Q2, although it remained negative.
  • Q2 reported net income was positive: Consolidated net income was $847,000, but investors should note that it included a $3.93 million gain from discontinued operations rather than profit from the ongoing business.
  • Asset values are concentrated in goodwill and intangibles: Goodwill and intangible assets totaled approximately $12.6 million, or roughly 75% of total assets, making book value sensitive to future impairment charges.
  • Financial comparisons are affected by restatements and discontinued operations: Several 2024 and 2025 figures were restated, and the latest quarter includes discontinued-operation activity, which limits the usefulness of simple year-over-year comparisons.
  • Continuing operations remain deeply unprofitable: Q2 2026 operating income was negative $2.70 million and continuing-operation net loss was $3.08 million despite the reported consolidated profit.
  • Gross margins have deteriorated sharply: Gross margin fell to approximately 13% in Q2 2026 from approximately 38% in Q1 2026 and 58% in Q2 2025, suggesting significant pressure on service economics or revenue mix.
  • Liquidity and dilution risks remain high: Cash declined to $454,000 while current liabilities were $8.10 million, and weighted-average basic shares rose from 16.4 million in Q2 2025 to 53.7 million in Q2 2026, indicating substantial shareholder dilution.
10/16/26 11:24 PM ETAI Generated. May Contain Errors.

Digital Health Acquisition Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Digital Health Acquisition's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Digital Health Acquisition's net income appears to be on a downward trend, with a most recent value of -$14.71 million in 2025, falling from -$3.24 million in 2022. The previous period was -$57.70 million in 2024.

Digital Health Acquisition's total operating income in 2025 was -$9.58 million, based on the following breakdown:
  • Total Gross Profit: $7.36 million
  • Total Operating Expenses: $16.94 million

Over the last 3 years, Digital Health Acquisition's total revenue changed from $0.00 in 2022 to $14.62 million in 2025, a change of 1,461,818,400.0%.

In the past 11 quarters, Digital Health Acquisition's cash and equivalents has ranged from $0.00 in Q1 2024 to $2.33 million in Q3 2024, and is currently $454.15 thousand as of their latest financial filing in Q2 2026.

Digital Health Acquisition had total debt of $2.23 million at the end of 2025, a 73.5% decrease from 2024, and none in 2022.

Over the last 3 years, Digital Health Acquisition's book value per share changed from -1.80 in 2022 to 0.27 in 2025.



Financial statements for NASDAQ:DHACW last updated on 9/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Elon Musk’s 4th Wealth Window Set to Open by October 30
Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...
Brownstone Research | Sponsoredtc pixel
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...
Weiss Ratings | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Did you grab your copy yet?
Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...
Profits Run | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel